SNDL Inc. (CSE: SNDL)
SNDL trades on the Canadian Securities Exchange in Life Sciences. Numbers below come from the TMX issuer list, Yahoo Finance closes and the Bank of Canada rate, each with its source.
Issuer list, sector and C$ market cap: TMX Group TSX and TSXV listed companies, as of November 16, 2026. US$ figures convert C$ at 1.4257 C$ per US$, the Bank of Canada daily rate for November 13, 2026. Close and returns: Yahoo Finance daily closes for SNDL.CN, last bar 2026-11-13, computed by MarginsX. Website: sociallinks: 40-F text ("our website").
Profile
| Field | Value |
|---|---|
| Ticker | SNDL on the Canadian Securities Exchange |
| Yahoo symbol | SNDL.CN |
| Sector | Life Sciences |
| Headquarters | The TMX list gives no head office |
| Listed | The TMX list gives no listing date |
| Listing type | TMX leaves listing type blank for long-listed issuers |
| Shares outstanding | 263,359,123 |
| Also listed on | No interlisting on the TMX list |
| Index membership | Not in an S&P/TSX index per the TMX list |
| SEC CIK | 0001766600 |
| Website | www.sndl.com |
| US listing | SNDL |
Returns
| Window | Return |
|---|---|
| 1 day | -2.5% |
| 1 week | -2.0% |
| 1 month | +16.2% |
| 3 months | +7.8% |
| 6 months | +0.5% |
| Year to date | -14.2% |
| 1 year | -18.5% |
| From 52-week high | -36.4% |
| 52-week range | C$1.62 to C$3.05 |
Links
SEDAR+ is linked for searching only; nothing on this page is taken from it.
Recent Canadian filings by type
105 documents in 12 types. Each title links to the document at its source.
Annual financial statements (2)
| Document | Type | Filed |
|---|---|---|
| Audited Consolidated Financial Statements of the Company and notes thereto for the years ended December 31, 2025 and 2024, together with the reports… Period 2025-12-31 | Annual financial statements (40-F) | 2026-03-12 |
| Audited Consolidated Financial Statements of the Company and notes thereto for the years ended December 31, 2024 and 2023, together with the reports… Period 2024-12-31 | Annual financial statements (40-F) | 2025-03-18 |
Interim financial statements (7)
| Document | Type | Filed |
|---|---|---|
| Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2026 Period 2026-09-30 | Interim financial statements (6-K) | 2026-10-27 |
| Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2026 Period 2026-06-30 | Interim financial statements (6-K) | 2026-07-28 |
| Condensed Consolidated Interim Financial Statements for the Three Months Ended March 31, 2026 Period 2026-03-31 | Interim financial statements (6-K) | 2026-04-29 |
| Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2025 Period 2025-09-30 | Interim financial statements (6-K) | 2025-11-04 |
MD&A (9)
| Document | Type | Filed |
|---|---|---|
| Management’s Discussion and Analysis of the Company for the year ended December 31, 2025 Period 2025-12-31 | MD&A (annual) (40-F) | 2026-03-12 |
| 2023 MD&A Period 2024-12-31 | MD&A (annual) (40-F) | 2025-03-18 |
| Management’s Discussion and Analysis for the Three and Nine Months Ended September 30, 2026 Period 2026-09-30 | MD&A (interim) (6-K) | 2026-10-27 |
| Management’s Discussion and Analysis for the Three and Six Months Ended June 30, 2026 Period 2026-06-30 | MD&A (interim) (6-K) | 2026-07-28 |
Annual information form (2)
| Document | Type | Filed |
|---|---|---|
| Annual Information Form of the Company for the year ended December 31, 2025 Period 2025-12-31 | Annual information form (40-F) | 2026-03-12 |
| 2023 AIF Period 2024-12-31 | Annual information form (40-F) | 2025-03-18 |
Material change report (2)
| Document | Type | Filed |
|---|---|---|
| MATERIAL CHANGE REPORT | Material change report (6-K) | 2025-04-17 |
| MATERIAL CHANGE REPORT | Material change report (6-K) | 2024-10-23 |
News release (35)
| Document | Type | Filed |
|---|---|---|
| PRESS RELEASE | News release (6-K) | 2026-10-27 |
| PRESS RELEASE | News release (6-K) | 2026-10-15 |
| PRESS RELEASE | News release (6-K) | 2026-10-14 |
| PRESS RELEASE | News release (6-K) | 2026-10-06 |
Management information circular / proxy (6)
| Document | Type | Filed |
|---|---|---|
| to this report on Form 6-K shall be deemed to be incorporated by reference in SNDL Inc.’s Period 2025-12-31 | Notice of meeting (6-K) | 2026-09-08 |
| Notice and Access Notification | Notice of meeting (6-K) | 2026-09-08 |
| to this report on Form 6-K shall be deemed to be incorporated by reference in SNDL Inc.s Period 2024-12-31 | Notice of meeting (6-K) | 2025-06-20 |
| Notice-and-Access Notice Period 2024-12-31 | Notice of meeting (6-K) | 2025-06-20 |
Annual report (2)
| Document | Type | Filed |
|---|---|---|
| 40-F Period 2025-12-31 | Annual report (40-F) (40-F) | 2026-03-12 |
| 40-F Period 2024-12-31 | Annual report (40-F) (40-F) | 2025-03-18 |
Early warning / ownership (3)
| Document | Type | Filed |
|---|---|---|
| Schedule 13G amendment | Schedule 13G (SCHEDULE 13G/A) | 2025-08-20 |
| Schedule 13G | Schedule 13G (SCHEDULE 13G) | 2025-08-14 |
| EARLY WARNING REPORT | Early warning report (6-K) | 2024-10-23 |
Insider report (3)
| Document | Type | Filed |
|---|---|---|
| Form 144 | Form 144 (144) | 2025-12-12 |
| Form 144 | Form 144 (144) | 2025-12-12 |
| Form 144 | Form 144 (144) | 2025-12-12 |
Certification (22)
| Document | Type | Filed |
|---|---|---|
| Form 52-109F2 Certificate of Interim Filings by CEO (pursuant to Canadian regulations) | Certification (52-109F2) (6-K) | 2026-10-27 |
| Form 52-109F2 Certificate of Interim Filings by CFO (pursuant to Canadian regulations) | Certification (52-109F2) (6-K) | 2026-10-27 |
| Form 52-109F2 Certificate of Interim Filings by CEO (pursuant to Canadian regulations) | Certification (52-109F2) (6-K) | 2026-07-28 |
| Form 52-109F2 Certificate of Interim Filings by CFO (pursuant to Canadian regulations) | Certification (52-109F2) (6-K) | 2026-07-28 |
Other (12)
| Document | Type | Filed |
|---|---|---|
| Consent of Independent Registered Public Accounting Firm Period 2025-12-31 | Consent (40-F) | 2026-03-12 |
| Consent of Independent Registered Public Accounting Firm Period 2025-12-31 | Consent (40-F) | 2026-03-12 |
| AUDITOR CONSENT Period 2024-12-31 | Consent (40-F) | 2025-03-18 |
| ARRANGEMENT AGREEMENT | Material contract / governance (6-K) | 2025-04-17 |
Sources: SEC EDGAR filings (public records). Documents filed only on SEDAR+ are not copied here; search SEDAR+ for the full record.
Trading halts
No CIRO halt notices for this company in our data.
Source: Canadian Investment Regulatory Organization (CIRO), Halts/Resumptions newsroom, notices since 2024-10-15.
Upcoming events
No upcoming earnings date, call or meeting announced in the SEC filings and newswire releases we read.
Recent
| Date | Time | Event | Webcast | Source |
|---|---|---|---|---|
| 2026-10-27 | 10:00 a.m. EDT | Q3 2026 earnings call | Webcast | SEC filing |
| 2026-10-27 | before markets open | Q3 2026 earnings release | No webcast link announced | SEC filing |
Source: dates read from the company's SEC filings and newswire releases; each row links to the announcement.
US private placements (SEC Form D)
| Filed | Securities | Sold | Offered | Filing |
|---|---|---|---|---|
| 2019-05-24 | Debt | US$40.7M | US$45.7M | SEC EDGAR |
Source: SEC EDGAR Form D filings matched on SEC CIK. Amounts are US$ as filed.
Peers in Life Sciences
| Ticker | Company | Exchange | Market cap (C$) | 1 month | 1 year |
|---|---|---|---|---|---|
| VREO | Vireo Growth Inc. | CSE | C$502.1M | -30.7% | -60.9% |
| FRX | Fennec Pharmaceuticals Inc. | TSX | C$522.2M | +14.3% | +50.8% |
| EPRX | Eupraxia Pharmaceuticals Inc. | TSX | C$640.1M | +21.5% | +32.7% |
| WEED | Canopy Growth Corporation | TSX | C$393.7M | -25.0% | -47.1% |
| ACB | Aurora Cannabis Inc. | TSX | C$372.0M | +15.4% | +14.4% |
The app has the price chart, every filing, private raises and the full peer set for SNDL.
Open in the app